Drug and Alcohol Dependence
Volume 91, Issue 2 , Pages 205-212 , 1 December 2007

A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence

  • Theresa Winhusen

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    • Cincinnati Addictions Research Center (CinARC), 3210 Jefferson Avenue, Cincinnati, OH 45220, USA
    • Corresponding Author InformationCorresponding author at: University of Cincinnati, 3210 Jefferson Avenue, Cincinnati, OH 45220, USA. Tel.: +1 513 487 7802; fax: +1 513 487 7819.
    • ,
  • Eugene Somoza

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    • Cincinnati Addictions Research Center (CinARC), 3210 Jefferson Avenue, Cincinnati, OH 45220, USA
    • Veterans Affairs Medical Center (VISN 10), 3200 Vine Street, Cincinnati, OH 45220, USA
    • ,
  • Ofra Sarid-Segal

      Affiliations

    • Department of Psychiatry, MDRU, VA Boston Healthcare System, Boston University School of Medicine, 720 Harrison Ave, Boston, MA 02118, USA
    • ,
  • R. Jeffrey Goldsmith

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    • Veterans Affairs Medical Center (VISN 10), 3200 Vine Street, Cincinnati, OH 45220, USA
    • ,
  • Judy M. Harrer

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    • Veterans Affairs Medical Center (VISN 10), 3200 Vine Street, Cincinnati, OH 45220, USA
    • ,
  • Florence S. Coleman

      Affiliations

    • Mental Health (116), Dayton VA Medical Center, 4100 West Third Street, Dayton, OH 45428, USA
    • ,
  • Roberta Kahn

      Affiliations

    • National Institute on Drug Abuse, Division of Treatment Research and Development, 6001 Executive Blvd, Rm 4123, Bethesda, MD 20892, USA
    • ,
  • Sabuhi Osman

      Affiliations

    • Cincinnati Addictions Research Center (CinARC), 3210 Jefferson Avenue, Cincinnati, OH 45220, USA
    • ,
  • Juris Mezinskis

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    • Veterans Affairs Medical Center (VISN 10), 3200 Vine Street, Cincinnati, OH 45220, USA
    • ,
  • Shou-Hua Li

      Affiliations

    • National Institute on Drug Abuse, Division of Treatment Research and Development, 6001 Executive Blvd, Rm 4123, Bethesda, MD 20892, USA
    • ,
  • Daniel Lewis

      Affiliations

    • Cincinnati Addictions Research Center (CinARC), 3210 Jefferson Avenue, Cincinnati, OH 45220, USA
    • ,
  • Maryam Afshar

      Affiliations

    • Department of Psychiatry, MDRU, VA Boston Healthcare System, Boston University School of Medicine, 720 Harrison Ave, Boston, MA 02118, USA
    • ,
  • Domenic A. Ciraulo

      Affiliations

    • Department of Psychiatry, MDRU, VA Boston Healthcare System, Boston University School of Medicine, 720 Harrison Ave, Boston, MA 02118, USA
    • ,
  • Paul Horn

      Affiliations

    • Cincinnati Addictions Research Center (CinARC), 3210 Jefferson Avenue, Cincinnati, OH 45220, USA
    • Veterans Affairs Medical Center (VISN 10), 3200 Vine Street, Cincinnati, OH 45220, USA
    • Department of Mathematics, University of Cincinnati, 2693 Campus Drive, Cincinnati, OH 45221, USA
    • ,
  • Margaret A. Montgomery

      Affiliations

    • National Institute on Drug Abuse, Division of Treatment Research and Development, 6001 Executive Blvd, Rm 4123, Bethesda, MD 20892, USA
    • ,
  • Ahmed Elkashef

      Affiliations

    • National Institute on Drug Abuse, Division of Treatment Research and Development, 6001 Executive Blvd, Rm 4123, Bethesda, MD 20892, USA

Received 15 December 2006 ,Revised 18 May 2007 ,Accepted 27 May 2007.

References 

  1. Bant WP. Antihypertensive drugs and depression: a reappraisal. Psychol. Med. 1978;8:275–283
  2. Baumeister AA, Hawkins MF, Uzelac SM. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J. Hist. Neurosci. 2003;12(2):207–220
  3. Berlant JL. Reserpine and phencyclidine-associated psychosis: three case reports. J. Clin. Psychiatry. 1985;46(12):542–544
  4. Berger P, Winhusen T, Somoza E, Harrer J, Mezinskis J, Leiderman D, et al. A medication screening trial evaluation of reserpine, gabapentin, and lamotrigine pharmacotherapy of cocaine dependence. Addiction. 2005;100(Suppl. 1):58–67
  5. Brief, D.J., Bollinger, A.R., Horton, G.E., LoCastro, J.S. Integrated treatment for addictions: education, motivational enhancement, and skills building for alcohol & drug addiction, unpublished manuscript.
  6. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 1988;85:5274–5278
  7. Fals-Stewart W, O’Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J. Consult. Clin. Psychol. 2000;68:134–144
  8. Florin SM, Kuczenski R, Segel DS. Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 1995;274:231–241
  9. Giachetti A, Shore PA. The reserpine receptor. Life Sci. 1978;23:89–92
  10. Gilmore HR. The treatment of chronic hypertension. Med. Clin. North Am. 1971;55:317–324
  11. Goodwin FK, Bunney WE. Depressions following reserpine: a reevaluation. Semin. Psychiatry. 1971;3:435–448
  12. Gorelick DA, Wilkins JN. Bromocriptine treatment for cocaine addiction: association with plasma prolactin levels. Drug Alcohol Depend. 2006;81:189–195
  13. Henry JP, Botton D, Sagne C, Isambert MF, Desnos C, Blanchard V, et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 1994;196:251–262
  14. Johnson BA, Wells LT, Roache JD, Wallace C, Ait-Daoud N, Wang Y. Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies. Am. J. Hypertens. 2005;18(6):813–822
  15. Maxwell JC. Emerging research on methamphetamine. Curr. Opin. Psychiatry. 2005;18(3):235–242
  16. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. J. Subst. Abuse Treat. 1992;9:199–213
  17. Mezinskis J, Dryenforth S, Goldsmith R, Cohen R, Somoza E. Craving and withdrawal symptoms for various drugs of abuse. Psychiatr. Ann. 1998;28:577–583
  18. Preston KL, Silverman K, Schuster CR, Cone EJ. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction. 1997;92:717–727
  19. Pubill D, Chipana C, Camins A, Pallas M, Camarasa J, Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol. 2005;204(1):57–68
  20. Sobell LC, Sobell M. Timeline follow back: a technique for assessing self-reported ethanol consumption. In:  Allen J,  Lit-ten R editor. Techniques to Assess Alcohol Consumption. New Jersey: Humana Press Inc.; 1992;p. 19–28
  21. Tracy K, Baker S, LoCastro J, Mezinskis J, Simon S, Somoza E. The Substance Clinical Global Impression (SCGI) Scale: measuring global functioning in substance related clinical trials. NIDA Res. Monogr. 2000;180
  22. Vocci F, Ling W. Medications development: successes and challenges. Pharmacol. Ther. 2005;108(1):94–108
  23. Wendy B. Do antihypertensive drugs really cause depression?. J. R. Soc. Med. 1974;67:919–923
  24. Widmer RB. Reserpine: the maligned antihypertensive drug. J. Fam. Pract. 1985;20:81–83
  25. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry. 1988;45:742–747

PII: S0376-8716(07)00231-1

doi: 10.1016/j.drugalcdep.2007.05.021

Drug and Alcohol Dependence
Volume 91, Issue 2 , Pages 205-212 , 1 December 2007

Article Tools

* Image Usage & Resolution